925 Shares in IDEXX Laboratories, Inc. $IDXX Purchased by RM Financial Services LLC

RM Financial Services LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 925 shares of the company’s stock, valued at approximately $626,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Park Place Capital Corp bought a new stake in IDEXX Laboratories in the 4th quarter valued at $29,000. WealthCollab LLC bought a new stake in IDEXX Laboratories in the 2nd quarter valued at $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in IDEXX Laboratories during the 3rd quarter valued at $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its holdings in IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on IDXX. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Finally, Citigroup started coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $556.94 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm has a market cap of $43.93 billion, a price-to-earnings ratio of 41.01, a P/E/G ratio of 3.17 and a beta of 1.55. The stock’s fifty day moving average price is $563.22 and its two-hundred day moving average price is $629.35. IDEXX Laboratories, Inc. has a one year low of $506.91 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the firm earned $2.91 earnings per share. The company’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.